PTC Therapeutics (PTCT) Misses Q4 EPS by 39c

PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.03), $0.39 worse than the analyst estimate of ($1.64). Revenue for the quarter came in at $165.2 million versus the consensus estimate of $150.83 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge